Akouos IPO Presentation Deck

AK-antiVEGF Overview 38 AK-antiVEGF Prevalence Indication Delivery Method Mechanism of Action Progress and Status AK-antiVEGF encodes a secreted inhibitor of vascular endothelial growth factor (VEGF) to treat vestibular schwannomas Estimated 200,000 cases in the US and EU AKOUOS Treatment of sporadic vestibular schwannoma, a common intracranial tumor • Current standard of care consists of surgical removal and/or radiation, both of which typically result in lost hearing and can be associated with significant morbidity Uses AAVAnc80 as a delivery vehicle to achieve local, sustained anti-VEGF protein at tumor site Administer product candidate directly into the inner ear Systemic anti-VEGF has been shown to reduce tumor volume and improve hearing in some patients with vestibular schwannoma • Local delivery may avoid the systemic side effects of high dose intravenous VEGF inhibitor infusion and could remove or reduce the need for other interventions Preclinical data in wild-type mice confirming anti-VEGF protein expression and tolerability • Completed dosing for a pilot non-human primate tolerability study and preparing to request a pre-IND meeting with FDA in 2H:20 CONFIDENTIAL

View entire presentation